Item 8.01 Other Events
On January 9, 2020, Michael Rice informed the board of directors (the "Board")
of Anchiano Therapeutics Ltd. (the "Company") of his decision to withdraw his
name from consideration for appointment to the Board as a nominee on behalf of
Clal Biotechnology Industries Ltd. ("CBI"). Mr. Rice is co-founder of LifeSci
Advisors, a life science investor relations firm that is engaged by the Company.
The Company previously disclosed, in its Form 8-K filed on January 2, 2020, the
receipt of a letter dated December 27, 2019 from CBI, demanding that the Board
convene a special general meeting to change the composition of the Board and
named Mr. Rice as a nominee.
© Edgar Online, source Glimpses